Edwards is focused on positioning TAVR for long-term growth ... those who received Edwards’ newest generation SAPIEN 3 Ultra RESILIA valve have experienced outstanding one-year outcomes.

Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

The first human TAVR was performed by Dr. Cribier in 2002. [33] There have been three generations of the Cribier-Edwards SAPIEN valve. The only valve that has FDA approval is the Edwards SAPIEN ...

The introduction of the Sapien X4 valve generation and the expected approval of Early TAVR for asymptomatic patients by mid-2025 will likely help Edwards maintain its leadership position in the ...

Within the Transcatheter Aortic Valve Replacement (TAVR) arm, Edwards Lifesciences is likely to have witnessed continued growth in procedures across the United States and worldwide. Continued strong ...

Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...

Eligible patients were randomized to receive the second-generation Edwards SAPIEN heart-valve system or usual care. Patients randomized to TAVR group received heparin therapy during the procedure ...

Within the Transcatheter Aortic Valve Replacement (TAVR) arm, Edwards Lifesciences is likely ... Continued strong demand for the company’s SAPIEN platform is expected to have acted as the ...